Key Takeaways from Alaunos Therapeutics Inc. (TCRT)’s Recent Sales and Margin Figures

Currently, Alaunos Therapeutics Inc. [TCRT] is trading at $0.60, up 1.69%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TCRT shares have lost -0.78% over the last week, with a monthly amount glided 11.11%, and seem to be holding up well over a long-time horizon.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


On 25, May 2023, Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting. In a post published today on Yahoo Finance, TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indications.

From an analyst’s perspective:

This stock has fluctuated between a low of $0.45 and a high of $4.01 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $3.03 within the next 12 months. Alaunos Therapeutics Inc. [NASDAQ: TCRT] shares were valued at $0.60 at the most recent close of the market. An investor can expect a potential return of 405.0% based on the average TCRT price forecast.

Analyzing the TCRT fundamentals

Gross Margin for this corporation currently stands at +5.58% with Operating Margin at -1205.95%, Pretax Margin comes in at -1291.24%, and Net Margin reading is -1291.24%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5847 points at the first support level, and at 0.5695 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6201, and for the 2nd resistance point, it is at 0.6403.

Alaunos Therapeutics Inc. [TCRT] reported earnings per share of -$0.04 for its fiscal quarter that ended on 3/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.04/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 12/30/2022 were -$0.04 per share as compared to estimates of -$0.07 per share, a difference of $0.03 representing a surprise of 42.90%.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Alaunos Therapeutics Inc. [NASDAQ:TCRT] is 2.20. Further, the Quick Ratio stands at 2.23, while the Cash Ratio is 2.19. Considering the valuation of this stock, the price to sales ratio is 48.23, the price to book ratio is 4.05.

Transactions by insiders

Recent insider trading involved Vieser Jaime, Director, that happened on Nov 29 when 1.25 million shares were purchased. Director, Postma Robert W completed a deal on Nov 29 to buy 0.75 million shares.